Literature DB >> 8540515

Is radical surgery in locally advanced gallbladder carcinoma justified?

C Bloechle1, J R Izbicki, B Passlick, K Gawad, C Passow, X Rogiers, H W Schreiber, C E Broelsch.   

Abstract

OBJECTIVES: Advanced gallbladder carcinoma is associated with a dismal long term prognosis. The aim of the present study was to evaluate the effectiveness of radical surgery in advanced stages of gallbladder carcinoma.
METHODS: The course of 66 patients operated for advanced gallbladder carcinoma was evaluated in a retrospective study; 14% of patients had stage II, 29% had stage III, and 57% had stage IV tumors. Twelve patients underwent cholecystectomy (CHE) and lymphadenectomy of the hepatoduodenal ligament (LA); 17 patients underwent cholecystectomy combined with segment IV/V liver resection (CHE+LR) and LA; and 10 patients underwent right extended hemihepatectomy (EHH). Complete tumor resection (R0) was achieved in six patients with CHE and LA, in 14 patients with CHE combined with segment IV/V LR and LA, and in all patients with right EHH. Resections with microscopic residual tumor (R1) were performed in nine patients. Mean follow-up was 15.4 months (range 3-90 months).
RESULTS: The perioperative mortality rate was 1.5%, and the morbidity rate was 20%. In R0 resections, mean survival was 23.3, 25.0, and 26.3 months for the patients who underwent CHE and LA, CHE combined with segment IV/V LR and LA, and right EHH, respectively. After 24 months, 46.4% of the patients with R0 resection were still alive compared with none of the patients with residual tumor. In the patients with R0 resection, no difference in survival was detected when node-negative status (pN0) was compared with positive locoregional lymph nodes (pN1a), whereas the degree of dedifferentiation (G2/G3) influenced survival.
CONCLUSIONS: If complete resection is achieved, radical surgical procedures, including segment IV/V liver resection and extended right hepatectomy, significantly improve survival rates with an acceptable morbidity and mortality rate.

Entities:  

Mesh:

Year:  1995        PMID: 8540515

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Resection after neoadjuvant chemotherapy in advanced carcinoma of the gallbladder: a retrospective study.

Authors:  Veda Padma Priya Selvakumar; Shuaib Zaidi; Pankaj Pande; Ashish Goel; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2015-01-22

2.  Significance of extensive surgery including resection of the pancreas head for the treatment of gallbladder cancer--from the perspective of mode of lymph node involvement and surgical outcome.

Authors:  Ryoko Sasaki; Hidenori Itabashi; Tomohiro Fujita; Yuichiro Takeda; Koichi Hoshikawa; Masahiro Takahashi; Osamu Funato; Hiroyuki Nitta; Senji Kanno; Kazuyoshi Saito
Journal:  World J Surg       Date:  2006-01       Impact factor: 3.352

3.  Is there a role for cholecystectomy in gallbladder carcinoma discovered to be unresectable for cure at laparotomy?

Authors:  Mallika Tewari; Vinay Kumar; Raghvendra R Mishra; Mohan Kumar; Hari S Shukla
Journal:  World J Surg       Date:  2008-12       Impact factor: 3.352

Review 4.  Gallbladder carcinoma incidentally encountered during laparoscopic cholecystectomy: how to deal with it.

Authors:  Ketao Jin; Huanrong Lan; Tieming Zhu; Kuifeng He; Lisong Teng
Journal:  Clin Transl Oncol       Date:  2011-01       Impact factor: 3.405

5.  Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.

Authors:  Manuel E González; Osvaldo H Giannini; Pablo González; Barbara Saldaña
Journal:  Clin Transl Oncol       Date:  2011-07       Impact factor: 3.405

6.  Outcome of radical surgery for carcinoma of the gallbladder according to the tumor node metastasis and Japanese Society of Biliary Surgery stages.

Authors:  Antonio Frena; Giuseppe La Guardia; Federico Martin
Journal:  J Gastrointest Surg       Date:  2004 Jul-Aug       Impact factor: 3.452

7.  Surgical management of biliary malignancy.

Authors:  T Peter Kingham; Victoria G Aveson; Alice C Wei; Jason A Castellanos; Peter J Allen; Daniel P Nussbaum; Yinin Hu; Michael I D'Angelica
Journal:  Curr Probl Surg       Date:  2020-06-30       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.